CancerGen's First Comparative Effectiveness Trial to Study Oncotype DX in Node-Positive Breast Cancer
October 21, 2009
CancerGen's First Comparative Effectiveness Trial to Study Oncotype DX in Node-Positive Breast Cancer
The Center for Comparative Effectiveness Research in Cancer Genomics expects its first clinical trial, which is investigating the predictive value of Genomic Health's Oncotype Dx in node-positive breast cancer patients, to serve as a model for future comparative effectiveness studies looking at genomic technologies in cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Oncotype DX Study Raises Questions About RT-PCR Testing for HER2 Expression
December 1, 2011 / PCR Insider - Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group
May 18, 2011 / Pharmacogenomics Reporter - Wall Street May Have 'Written Off' Genomic Health's Colon Cancer Dx, But Survey Shows Some Docs Haven't
July 15, 2009 / Pharmacogenomics Reporter - With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter - Wall Street Closely Tracking Validation Data on Genomic Health's Oncotype DX Prostate Cancer Test
April 3, 2013 / Pharmacogenomics Reporter